STOCK TITAN
  1. Home
  2. News
  3. ATNM

Actinium Pharmaceuticals Inc - ATNM STOCK NEWS

Welcome to our dedicated news page for Actinium Pharmaceuticals (Ticker: ATNM), a resource for investors and traders seeking the latest updates and insights on Actinium Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Actinium Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Actinium Pharmaceuticals's position in the market.

News
Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy Combinations
Rhea-AI Summary
Actinium Pharmaceuticals presented data at the Society of Immunotherapy of Cancer (SITC) 38th Annual Meeting, highlighting Actimab-A's ability to target and deplete myeloid-derived suppressor cells (MDSCs) in solid tumors. The data showed that Actimab-A reduced cancer patient-derived MDSCs and restored T cell proliferation and effector function. In addition, Actimab-A significantly depleted MDSCs in tumor-bearing humanized mice. The company believes that Actimab-A has the potential to be used in combination with immunotherapy to enhance antitumor immunity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.41%
Tags
clinical trial
-
News
Actinium Appoints Lynn Bodarky as Chief Business Officer
Rhea-AI Summary
Actinium Pharmaceuticals has appointed Lynn Bodarky as Chief Business Officer to lead the company's business development, licensing, and collaboration activities. Ms. Bodarky brings over 25 years of experience in business development and licensing, having executed transactions totaling over $5 billion in value across oncology, autoimmune, and neurological indications. Actinium is a leader in the development of targeted radiotherapies, with a pipeline of highly differentiated therapies and expertise in alpha-emitter payload Actinium-225. The company has positive Phase 3 data for Iomab-B, a CRADA with the NCI, an NIH grant for Iomab-ACT, and novel preclinical solid tumor data. Actinium aims to leverage Ms. Bodarky's extensive experience to bring their radiotherapeutics to patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.93%
Tags
management
-
News
Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023
Rhea-AI Summary
Actinium Pharmaceuticals, Inc. will be attending Bio-Europe, the largest biopharmaceutical industry partnering event in Europe, from November 6 - 8, 2023 in Munich, Germany. Actinium is developing targeted radiotherapies, including Iomab-B for bone marrow transplant conditioning, which met the primary endpoint in the Phase 3 SIERRA trial. Actinium is also advancing other clinical-stage targeted radiotherapeutics and solid tumor programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.93%
Tags
conferences
News
Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA Trial
Rhea-AI Summary
Actinium Pharmaceuticals announced that three abstracts detailing results from the Phase 3 SIERRA trial of Iomab-B in relapsed or refractory acute myeloid leukemia (AML) patients have been accepted for presentation at the ASH conference. The trial showed that AML patients with a TP53 mutation who received Iomab-B and a bone marrow transplant had a median overall survival of 5.49 months compared to 1.66 months in patients who did not receive Iomab-B. Iomab-B also demonstrated similar overall survival outcomes in TP53 negative patients. 24% of patients enrolled in the trial had a TP53 mutation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.5%
Tags
clinical trial
-
News
Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell Therapy
Rhea-AI Summary
Actinium Pharmaceuticals receives NIH grant extension for clinical collaboration with Memorial Sloan Kettering Cancer Center to study Iomab-ACT for targeted conditioning prior to CAR-T cell therapy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
clinical trial
-
News
Actinium Pharma Highlights Abstract Accepted for Poster Presentation at the SITC 38th Annual Meeting
Rhea-AI Summary
Actinium Pharmaceuticals details abstract accepted for poster presentation at SITC 38th Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
none
News
Actinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHO
Rhea-AI Summary
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) highlighted updated survival data from its Phase 1b trial evaluating Actimab-A in combination with salvage chemotherapy CLAG-M for high-risk relapsed or refractory acute myeloid leukemia (r/r AML) patients. The data showed a 30-month median overall survival (OS) in patients with prior venetoclax treatment and a 24-month median OS in all patients proceeding to bone marrow transplant (BMT) following Actimab-A + CLAG-M. Additionally, Actimab-A demonstrated enhanced anti-leukemic activity with FLT3 inhibitors in preclinical studies, supporting its clinical evaluation in combination with FLT3 inhibitors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
clinical trial
-
News
Actinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual Meeting
Rhea-AI Summary
Actinium Pharmaceuticals details three abstracts accepted for poster presentation at SOHO 2023 Annual Meeting, showcasing positive results of their treatments for AML.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
none
-
News
SNMMI 2023 Annual Meeting Abstract of the Year Awarded to Actinium's Iomab-B Phase 3 SIERRA Data
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
clinical trial
News
Actinium Pharma Highlights Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual Meeting
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.94%
Tags
none
Stock ATNM logo
Actinium Pharmaceuticals Inc

NYSE:ATNM

ATNM Rankings

#3781 Ranked by Market Cap
#4913 Ranked by Stock Gains
N/A Ranked by Dividends

ATNM Stock Data

227.53M
28.61M
2.16%
24.57%
7.44%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About ATNM

actinium pharmaceuticals, inc. (www.actiniumpharma.com) (nyse mkt: atnm) is a new york-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. the company’s lead radiopharmaceutical iomab™-b will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. the company is preparing a single, pivotal, multicenter phase 3 clinical study of iomab™-b in refractory and relapsed acute myeloid leukemia (aml) patients over the age of 55 with a primary endpoint of durable complete remission. the company’s second program, actimab-a, is continuing its clinical development in a phase 1/2 trial for newly diagnosed aml patients o